Last updated: August 18, 2026
Antara was a U.S. branded formulation of micronized fenofibrate for hypertriglyceridemia and mixed dyslipidemia. Its commercial position weakened after generic fenofibrate products entered the market and competing branded formulations, including Tricor, Triglide, Lipofen and Fenoglide, established broader distribution. Antara does not have a meaningful current exclusivity position, and its standalone revenue is not publicly disclosed. The economic profile is now primarily a generic-market question rather than a branded-growth opportunity.
What is Antara micronized fenofibrate?
Antara contains micronized fenofibrate, a lipid-regulating drug in the fibrate class. The product was approved in the United States in 2005 under NDA 21-756 in 43 mg and 87 mg strengths.[1]
| Attribute |
Antara |
| Active ingredient |
Micronized fenofibrate |
| Drug class |
Fibric acid derivative |
| Original U.S. dosage form |
Oral capsule |
| U.S. strengths |
43 mg and 87 mg |
| FDA approval |
2005 |
| Original sponsor |
Oscient Pharmaceuticals |
| Primary indications |
Severe hypertriglyceridemia and mixed dyslipidemia |
| Primary competitors |
Tricor, Triglide, Lipofen, Fenoglide and generic fenofibrate |
| Current commercial profile |
Mature or discontinued branded product with generic substitution |
Fenofibrate activates peroxisome proliferator-activated receptor alpha and reduces triglycerides while increasing high-density lipoprotein cholesterol. Product labeling also warns about liver toxicity, gallbladder disease, creatinine changes and myopathy risk, especially when used with statins.[1]
When did Antara lose market exclusivity?
Antara’s commercial exclusivity ended through the combination of an old active ingredient, limited formulation differentiation and generic entry. Fenofibrate had been marketed in other formulations before Antara, so Antara did not receive the economic protection associated with a new chemical entity.
The product’s competitive barrier was the micronization and formulation technology, not the underlying molecule. Once manufacturers developed and obtained approval for therapeutically equivalent or pharmaceutically comparable products, prescribers and pharmacy benefit managers had strong incentives to substitute lower-cost versions.
Antara exclusivity timeline
| Period |
Market event |
Commercial effect |
| 2005 |
FDA approval of Antara |
Initial branded launch opportunity |
| Late 2000s |
Expansion of branded fenofibrate competition |
Reduced differentiation |
| Around 2010 |
Oscient financial distress and bankruptcy proceedings |
Distribution and commercial-support risk |
| 2010s |
Broad generic fenofibrate availability |
Price compression and substitution |
| Current market |
Mature generic fibrate category |
Limited branded pricing power |
The key commercial loss was not a single patent cliff. Antara faced a cumulative erosion process caused by pre-existing fenofibrate products, multiple branded competitors and generic competition.
What patents protected Antara micronized fenofibrate?
The strongest historical intellectual-property claims in the fenofibrate market generally concerned particle size, dissolution, bioavailability and dosage-form design. Antara’s practical protection was narrower than molecule-level exclusivity because fenofibrate was already known.
The FDA Orange Book remains the principal source for identifying patents listed against a prescription drug product and for evaluating whether an approved product has current listed patent protection.[2] Antara should not be treated as having a live, commercially meaningful patent estate unless a current Orange Book review identifies active listings against the relevant NDA.
Formulation patents and technical barriers
Micronization can improve dissolution for a poorly water-soluble compound. A formulation patent may cover:
- Micronized fenofibrate particles
- Particle-size distributions
- Excipients and carrier systems
- Dissolution profiles
- Solid-dose compositions
- Bioavailability improvements
- Manufacturing and blending processes
These claims can create development costs for generic manufacturers, but they generally do not preserve durable pricing power after multiple alternative formulations receive approval.
Historical fenofibrate patent families associated with branded products included formulation and bioavailability claims held by companies such as Fournier, Abbott and other product sponsors. Those patent families were linked primarily to products such as Tricor and related fenofibrate formulations rather than providing Antara with a current, standalone monopoly.
What is the Orange Book status of Antara?
The commercial relevance of Antara’s Orange Book status is limited because the product is not a current growth brand and generic fenofibrate products are widely available. FDA Orange Book records should be used to distinguish among three separate issues:
- Whether the Antara NDA remains listed.
- Whether the product is listed as discontinued or withdrawn.
- Whether any patents remain listed against the NDA.
A product’s appearance in the Orange Book does not establish active commercial distribution. FDA’s discontinued-drug records and Drugs@FDA provide separate information on marketing status.[2,3]
Antara’s historical product status also has to be distinguished from safety withdrawal. A product can leave the market because of commercial discontinuation, sponsor bankruptcy, portfolio rationalization or weak demand rather than because FDA determined that the drug was unsafe or ineffective.
Were there Paragraph IV challenges to Antara?
Paragraph IV litigation was more commercially significant for major fenofibrate products, particularly Tricor, than for Antara. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed. Generic applicants use that pathway to seek approval before listed patent expiration.
Public Hatch-Waxman litigation involving fenofibrate included disputes over formulation, bioavailability and listed patents associated with leading branded products. The high-profile cases generally centered on Tricor and related Abbott or Fournier products, not on Antara as a major standalone litigation asset.[4]
The absence of a current high-value Antara patent dispute is commercially consistent with the product’s mature status. Generic companies no longer need to challenge a meaningful Antara monopoly when multiple fenofibrate products are already available.
What FDA regulatory status applies to Antara?
Antara was approved through the full NDA pathway. Generic fenofibrate products are generally approved through abbreviated new drug applications, which require pharmaceutical equivalence and bioequivalence to the relevant reference product or another FDA-recognized reference standard.[3]
The regulatory issues most relevant to Antara include:
- Dose equivalence across micronized and nonmicronized products
- Bioequivalence for different strengths
- Dissolution performance
- Labeling for triglyceride reduction and mixed dyslipidemia
- Renal dosing and contraindications
- Co-administration with statins
- Manufacturing consistency for particle-size control
The product is a small-molecule drug. Biosimilar risk is therefore not applicable. Competitive risk comes from conventional generic ANDAs, authorized generics, therapeutic substitution and alternative lipid-lowering therapies.
How many products compete with Antara?
The fenofibrate category is structurally crowded. Competition comes from several branded products, generic fenofibrate strengths and non-fibrate therapies.
| Competitive segment |
Examples |
Effect on Antara |
| Branded fenofibrate |
Tricor, Triglide, Lipofen, Fenoglide |
Reduced brand differentiation |
| Generic fenofibrate |
Multiple manufacturers and dosage forms |
Direct price pressure |
| Other fibrates |
Gemfibrozil |
Therapeutic substitution |
| Statins |
Atorvastatin, rosuvastatin, simvastatin |
Compete for dyslipidemia treatment budgets |
| Prescription omega-3 products |
Icosapent ethyl and omega-3 formulations |
Compete in triglyceride management |
| Lifestyle and metabolic treatment |
Diet, weight loss and diabetes treatment |
Reduces drug demand in some patients |
Statins remain the dominant pharmacologic treatment for cardiovascular risk reduction. Fenofibrate demand is more concentrated in patients with severe hypertriglyceridemia, mixed dyslipidemia or situations where clinicians seek additional triglyceride lowering.
What is the financial trajectory for Antara?
Antara’s financial trajectory has three phases:
Launch and early commercialization
The initial value proposition was a branded micronized fenofibrate product with a familiar lipid-lowering mechanism and an established clinical category. Revenue potential was constrained by the presence of Tricor and other fenofibrate products.
Commercial disruption
Oscient’s financial problems materially weakened the product’s prospects. Oscient filed for bankruptcy protection in 2010 and subsequently pursued asset sales and restructuring.[5] A product supported by a distressed sponsor is vulnerable to supply interruptions, lower promotional spending, wholesaler delisting and transfer of commercial rights.
Generic erosion
Once generic fenofibrate became widely available, the market shifted from branded prescribing to pharmacy-level substitution. Gross sales, net price and prescription share likely declined sharply, although product-specific Antara revenue is not reported in public filings with sufficient consistency to establish a reliable annual series.
| Financial driver |
Direction for Antara |
Business implication |
| Generic entry |
Negative |
Lower price and prescription retention |
| Multiple branded competitors |
Negative |
Higher substitution risk |
| Sponsor bankruptcy |
Negative |
Distribution and promotion disruption |
| Old active ingredient |
Negative |
No molecule-level exclusivity |
| Micronized formulation |
Initially positive |
Limited differentiation after generic replication |
| Severe hypertriglyceridemia demand |
Positive |
Supports residual category demand |
| Statin dominance |
Negative |
Limits broader dyslipidemia growth |
| PBM substitution |
Negative |
Reduces branded net revenue |
There is no defensible basis for treating Antara as a current material revenue contributor without company-level sales disclosures. The appropriate valuation assumption is nominal or zero standalone branded revenue unless a rights holder reports active sales.
Which companies challenged the fenofibrate market?
The competitive landscape included originator and specialty pharmaceutical companies rather than a single dominant challenger.
| Company |
Product or role |
Strategic relevance |
| Oscient Pharmaceuticals |
Antara |
Original Antara sponsor |
| Abbott Laboratories |
Tricor and related fenofibrate products |
Major branded competitor and patent litigant |
| Fournier |
Fenofibrate development and formulation rights |
Important historical originator presence |
| SkyePharma |
Triglide technology and product partnership |
Formulation-based competition |
| Kowa Pharmaceuticals |
Lipofen |
Alternative branded fenofibrate |
| Santarus |
Fenoglide |
Formulation and absorption differentiation |
| Generic manufacturers |
Fenofibrate products |
Main source of price erosion |
Ownership and marketing rights changed over time. Corporate records should be used to separate original sponsorship, current authorization, manufacturing and distribution rights.
What generic launch risks exist for Antara?
Generic entry risk is effectively realized rather than prospective. The main risk has shifted from a potential first generic launch to continued price compression and loss of channel access.
Generic manufacturers face lower technical barriers than they would for a complex product, but they still must control:
- Fenofibrate particle size
- Dissolution and bioavailability
- Capsule or tablet uniformity
- Impurity levels
- Stability
- Site-transfer consistency
- FDA inspection and supply compliance
The market can support several suppliers because manufacturing is less complex than for biologics, sterile injectables or highly specialized delivery systems. That creates a low-margin environment in which manufacturers compete on cost, wholesaler reliability and contract access.
How does Antara compare with Tricor and generic fenofibrate?
| Factor |
Antara |
Tricor |
Generic fenofibrate |
| Brand recognition |
Limited to moderate |
High |
None at product level |
| Active ingredient |
Micronized fenofibrate |
Fenofibrate formulations |
Fenofibrate |
| Patent position |
No evident current commercial moat |
Historically stronger formulation estate |
Generally exposed to substitution |
| Pricing power |
Low |
Historically higher |
Lowest |
| Prescriber pull |
Limited |
Established historical brand |
Driven by formulary and pharmacy substitution |
| Revenue outlook |
Declining or inactive |
Mature, erosion-exposed |
Volume-driven, low margin |
| Strategic value |
Limited |
Portfolio or litigation value historically |
Manufacturing scale and supply reliability |
Tricor had greater commercial scale and a more visible patent strategy. Antara’s smaller position made it less able to sustain promotion or defend premium pricing. Generic fenofibrate has the strongest cost position but the weakest brand economics.
What patent litigation and settlements affected the market?
Fenofibrate litigation largely involved attempts by generic applicants to enter before expiration of formulation and bioavailability patents covering branded products. Settlements in pharmaceutical patent cases can include delayed-entry dates, licenses, authorized-generic arrangements and manufacturing restrictions. The economic effect depends on the settlement terms and the remaining patent life.
For Antara specifically, the central commercial conclusion is that historical fenofibrate litigation did not preserve a durable, current monopoly. The relevant patent disputes have expired, been resolved or become commercially immaterial as generic products gained broad access.[4]
What geographic coverage does Antara have?
Antara was principally a U.S. product. Its value was tied to U.S. FDA approval, U.S. reimbursement and U.S. distribution. International fenofibrate markets were served by different brands, local marketing authorizations and country-specific generic manufacturers.
No global revenue thesis should be attributed to Antara without separate evidence of foreign approvals, licensing agreements or active international sales. The product’s commercial history is best analyzed as a U.S. branded-drug and generic-substitution case.
How strong is the Antara patent estate?
Antara’s patent estate is weak as a current commercial asset.
| Patent-strength factor |
Assessment |
| New chemical entity protection |
None |
| Current molecule exclusivity |
None |
| Formulation differentiation |
Historically relevant |
| Current Orange Book leverage |
Limited or absent |
| Generic blocking power |
Low |
| Manufacturing complexity |
Moderate but manageable |
| Litigation value |
Low |
| Licensing value |
Low unless tied to an active product or technology |
The formulation technology had commercial value during the branded period. It does not support a strong present-day licensing or litigation thesis.
Key Takeaways
- Antara was a branded micronized fenofibrate product approved by FDA in 2005.
- Its market position was weakened by Tricor, Triglide, Lipofen, Fenoglide and generic fenofibrate.
- Oscient’s 2010 bankruptcy created additional commercial and distribution pressure.
- Fenofibrate is an old small-molecule active ingredient with no current molecule-level exclusivity.
- The product’s historical protection centered on formulation, particle size, dissolution and bioavailability.
- Generic entry and pharmacy substitution eliminated meaningful branded pricing power.
- Antara’s standalone revenue is not publicly reported and should not be modeled as a material current revenue stream.
- Biosimilar competition is irrelevant because fenofibrate is a conventional small molecule.
- The remaining business opportunity is in low-cost generic supply, not premium branded commercialization.
- Antara has limited current patent, licensing or litigation value.
FAQs
Is Antara still available in the United States?
Antara has limited current commercial relevance, and its availability should be distinguished from historical FDA approval. FDA Drugs@FDA, the Orange Book and current wholesaler records are the appropriate sources for confirming whether any active product remains distributed.[2,3]
Is Antara the same as generic fenofibrate?
Antara contains micronized fenofibrate, but generic products must be evaluated by dosage form, strength, labeling and FDA reference-product status. A pharmacy substitution decision depends on the specific approved product.
Did Antara have pediatric exclusivity?
Antara was not known for a commercially relevant pediatric exclusivity period. Its value derived from adult dyslipidemia treatment and formulation positioning.
Can a company still license Antara rights?
A license could exist contractually even if the product has little market value. The economic value would depend on active manufacturing rights, FDA listing status, supply rights and any surviving intellectual property.
Is fenofibrate still commercially attractive?
Fenofibrate remains commercially relevant as a low-cost generic for selected triglyceride and mixed-dyslipidemia patients. The category is unattractive for premium branded pricing because of generic competition, statin dominance and multiple alternative therapies.
References
-
U.S. Food and Drug Administration. (2005). Antara (fenofibrate) capsules prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA and discontinued drug product records. FDA.
-
U.S. Court of Appeals for the Federal Circuit. (2012). Abbott Laboratories v. Sandoz, Inc. and related fenofibrate patent litigation decisions. Federal Circuit.
-
U.S. Bankruptcy Court for the District of Delaware. (2010). In re Oscient Pharmaceuticals Corporation, Chapter 11 proceedings. U.S. Bankruptcy Court.
-patent-expirations.png "ANTARA (MICRONIZED) drug patent expirations")
